Opdivo for Melanoma Adjuvant Therapy – Details

Details

Files
Generic Name:
Nivolumab
Project Status:
Complete
Therapeutic Area:
Melanoma Adjuvant Therapy
Manufacturer:
Bristol-Myers Squibb Canada
Brand Name:
Opdivo
Project Line:
Reimbursement Review
Project Number:
PC0147-000
NOC Status at Filing:
Pre NOC
Strength:
40 mg & 100 mg
Tumour Type:
Skin & Melanoma
Indications:
Melanoma Adjuvant Therapy
Funding Request:
For the adjuvant treatment of adult patients after complete resection of melanoma with regional lymph node involvement, in transit metastases/satellites without metastatic nodes, or distant metastases
Review Status:
Notification to Implement Issued
Pre Noc Submission:
Yes
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.